[1]Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
[2]Hanahan D, Weinberg RA. Hallmarks of cancer : the next generation. Cell. 2011;144:646-74.
[3]Cheever MA. The prioritization of cancer antigens : a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323-37.
[4]Schreiber RD. Cancer immunoediting : integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565-70.
[5]Mittal D. New insights into cancer immunoediting and its three components phases – elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16-25.
[6]Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62-8.
[7]Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39:61-73.
[8]Wolchok JD. Monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-64.
[9]Brahmer AH. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65.
[10]Topalian SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
[11]Larkin J. Combined and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.